Crohn's disease commonly affects children and adolescents.
However the majority of research into the safety and efficacy of therapies for inflammatory bowel disease, has occurred only in adults.
In this study, researchers from Ohio, USA, sought to determine the rate of reactions in children following infliximab infusions, and to identify predictive variables.
The research team performed a retrospective review of all infliximab infusions performed at Columbus Children's Hospital from 1998 to 2001.
Overall, 57 children received 361 infusions.
|Use of immunosuppressive medications for less than 4 months is a risk factor for reaction.|
|Alimentary Pharmacology and Therapeutics|
Of the 361 infusions, 355 (98%) were completed.
In addition, 50 children had 304 repeat infusions.
The team found that there were a total of 35 infusion related reactions.
They also determined that female gender, and the use of immunosuppressive medications for less than 4 months, were risk factors for a reaction to infusion number 2.
Furthermore, a reaction to infusion 2, and immunosuppressive use for less than 4 months, were risk factors for infusion number 3.
Drs Crandall and Mackner concluded, "The rate of infusion reactions in children receiving infliximab is similar to that in adults".
"Female gender, immunosuppressive use for less than 4 months and prior infusion reactions may be risk factors for subsequent infusion reactions in children".